Robust tolerance to fully allogeneic islet transplants achieved by chimerism with minimal conditioning

Transplantation. 2005 Aug 15;80(3):370-7. doi: 10.1097/01.tp.0000167724.38038.ae.

Abstract

Background: Whether mixed chimeras induced by nonmyeloablative conditioning are tolerant to challenge with donor allogeneic islet grafts is unknown. Here we investigate whether our nonmyeloablative, costimulation blockade-free and sirolimus (SRL)-based protocol could facilitate mixed chimerism via bone marrow transplantation (BMT) and induce islet allograft tolerance.

Methods: After low dose (1-3 Gy) total body irradiation (TBI, day -1), with or without prior lymphocyte depletion, C57BL/6 mice were transfused with 40 x 10(6) BALB/c bone marrow cells (day 0) and received SRL (3 mg/kg/day) for 4 weeks. Chimerism was monitored by flow cytometry and the recipients were rendered diabetic chemically and challenged with donor islets.

Results: Mixed chimerism was achieved in mice treated with TBI 3 Gy/SRL but it declined over time in 60% (9/15) of them. Long-term stable chimerism was established in 100% of recipients over 50 weeks with either antilymphocyte serum (ALS, 9/9), anti-CD4 (4/4), or anti-CD4 plus anti-CD8 (5/5) prior to BMT. TBI conditioning could be reduced to 1 Gy, with 90% (9/10) maintaining chimerism in the long-term. When TBI was substituted with cyclophosphamide (CTX) or busulfan (BUS), all mice remained chimeric in the long-term. The chimeras showed no proliferative response to donor antigen and accepted both first and second donor-specific islet grafts indefinitely while rejecting third-party grafts.

Conclusions: This data provides the first evidence that stable fully allogeneic chimeras induced with BMT after nonmyeloablative conditioning with SRL and lymphocyte-depleting antibodies exhibit robust donor-specific tolerance to islet grafts.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bone Marrow Cells / cytology
  • Bone Marrow Transplantation / methods
  • Busulfan / pharmacology
  • CD4 Antigens / biosynthesis
  • CD40 Ligand / chemistry
  • CD8 Antigens / biosynthesis
  • Cyclophosphamide / pharmacology
  • Diabetes Mellitus, Experimental
  • Flow Cytometry
  • Immunosuppressive Agents / pharmacology
  • Islets of Langerhans / cytology*
  • Lymphocyte Culture Test, Mixed
  • Lymphocyte Depletion
  • Lymphocytes / cytology
  • Mice
  • Mice, Inbred BALB C
  • Mice, Inbred C57BL
  • Mice, Inbred CBA
  • Phenotype
  • Sirolimus / pharmacology
  • T-Lymphocytes / immunology
  • Time Factors
  • Transplantation Chimera / immunology*
  • Transplantation Conditioning / methods*
  • Transplantation Tolerance*
  • Transplantation, Homologous / methods*
  • Treatment Outcome

Substances

  • CD4 Antigens
  • CD8 Antigens
  • Immunosuppressive Agents
  • CD40 Ligand
  • Cyclophosphamide
  • Busulfan
  • Sirolimus